Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-EGF (Panitumumab) in Metastatic Colorectal Carcinoma
NCT00111774Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of panitumumab in colorectal cancer (CRC) (2 arms), sponsored by Amgen. Primary endpoint: Objective Response at Week 8. Started Mar 2002; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00111774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111774.